» Articles » PMID: 17598957

Mechanism of Abnormal Intestinal Motility in Inflammatory Bowel Disease: How Smooth Muscle Contraction is Reduced?

Overview
Specialty Physiology
Date 2007 Jun 30
PMID 17598957
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Intestinal inflammation alters the contractile activity of intestinal smooth muscle. Motility disorders of the gastrointestinal tract are clinically important symptoms, because they are often associated with severe interstitial inflammation. In addition, the motility disorders secondarily induce abnormal growth of the intestinal flora, and the resulting disturbance of this flora aggravates the pathogenesis of mucosal inflammation. This in turn aggravates the intestinal dysmotility; i.e., it is an inflammatory spiral. Therefore, it is important to elucidate the mechanisms involved in the changes in motor function which occur in intestinal inflammation. Recent studies have revealed several molecular mechanisms responsible for the decreased motility which occurs in an inflamed gastrointestinal tract. In the present review, we discuss the functional failure of smooth muscle cells, including changes in the activity of muscarinic receptors, ion channels and the endogenous myosin phosphatase inhibitor CPI-17.

Citing Articles

Interstitial cells of Cajal in gastrointestinal inflammatory diseases.

Kaji N, Hori M J Smooth Muscle Res. 2023; 59:1-13.

PMID: 36792171 PMC: 9926098. DOI: 10.1540/jsmr.59.1.


Relation of gut microbiota and postoperative gastrointestinal dysfunction in older patients with colon cancer undergoing elective colon resection: a protocol for a prospective, observational cohort study.

Wang N, Zuo H, Xu Y, Zhou Y, Wei A, Li K BMJ Open. 2023; 12(9):e057391.

PMID: 36691223 PMC: 9462128. DOI: 10.1136/bmjopen-2021-057391.


Pharmacological basis of bergapten in gastrointestinal diseases focusing on H/K ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs.

Aslam H, Khan A, Qazi N, Ali F, Hassan S, Bungau S Front Pharmacol. 2022; 13:1005154.

PMID: 36467058 PMC: 9709249. DOI: 10.3389/fphar.2022.1005154.


Altered functional responses by PAR1 agonist in murine dextran sodium sulphate-treated colon.

Sung T, Moon S, Perrino B, Sanders K, Koh S Sci Rep. 2022; 12(1):16746.

PMID: 36202914 PMC: 9537183. DOI: 10.1038/s41598-022-21285-2.


Esculentoside A Alleviates Intestinal Dysmotility in Ulcerative Colitis by Regulating HS/CSE and NO/nNOS Systems.

Liu Y, Wei W, Liang S, Fang H, Cao J Evid Based Complement Alternat Med. 2022; 2022:7757833.

PMID: 36091585 PMC: 9451963. DOI: 10.1155/2022/7757833.